Welcome to our dedicated page for Pulmonx news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx stock.
Pulmonx Corp (Nasdaq: LUNG) delivers innovative minimally invasive solutions for severe lung diseases, including its FDA-cleared Zephyr Valve system. This news hub provides essential updates for stakeholders tracking medical advancements and corporate developments in interventional pulmonology.
Access real-time updates on clinical trial milestones, regulatory approvals, and strategic partnerships that shape treatment paradigms for emphysema and COPD. Our curated collection features earnings reports, product launch details, and peer-reviewed research findings - all vital for understanding Pulmonx's market position.
Key content includes analysis of pulmonary treatment innovations, global commercialization efforts, and financial performance metrics. Investors and healthcare professionals will find timely information on FDA submissions, international expansion, and clinical outcome studies that demonstrate improved patient quality of life.
Bookmark this page for centralized access to Pulmonx's latest advancements in bronchoscopic lung volume reduction technology. Stay informed about developments that impact both respiratory care standards and long-term corporate growth strategies.
Pulmonx (Nasdaq: LUNG) reported strong financial results for Q2 2024. The company achieved record worldwide revenue of $20.8 million, a 21% increase year-over-year. U.S. revenue grew 26% to $13.9 million, while international revenue increased 12% to $6.9 million. Gross margin remained steady at 74%.
Key highlights include:
- Addition of 17 new Zephyr® Valve U.S. treatment centers
- First U.S. patients treated with AeriSeal® System in CONVERT II trial
- Net loss of $15.3 million, or $0.39 per share
- Adjusted EBITDA loss of $7.6 million
Pulmonx maintains its 2024 revenue guidance of $81-84 million and expects gross margin to be 74-75%.
Pulmonx (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston. The company's management is set to present on Tuesday, August 13, 2024, at 5:00 AM PT / 8:00 AM ET.
Investors and interested parties can access a live and archived webcast of the presentation through the 'Investors' section of the Pulmonx website. This conference provides an opportunity for Pulmonx to showcase its innovations and growth strategies in the field of lung disease treatments to a wider audience of investors and industry professionals.
Pulmonx, a leader in minimally invasive lung disease treatments, will release its Q2 2024 financial results on July 31, 2024. The announcement will be made post-market close, and a conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. Investors can access both live and archived webcasts on Pulmonx's investor relations website.
Pulmonx announced the grant of inducement awards to Mehul Joshi, the new Chief Financial Officer, consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock. The stock option grant has an exercise price of $9.28 per share and will vest over a three-year period, while the restricted stock units will vest over four years. The awards were approved as an inducement to Mr. Joshi's employment under Nasdaq Listing Rule 5635(c)(4).
Pulmonx (Nasdaq: LUNG) reported financial results for Q1 2024, achieving a 30% year-over-year revenue growth, recording $18.9 million in worldwide revenue, with $12.9 million in U.S. revenue. The company realized a gross margin of 75% and treated the first patient in significant clinical trials. Pulmonx appointed new executives to drive growth and expects revenue for 2024 to be in the range of $81 million to $84 million.
FAQ
What is the current stock price of Pulmonx (LUNG)?
What is the market cap of Pulmonx (LUNG)?
